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Wehave generated a set of dual-reporter human cell lines and
devised a chase protocol to quantify proteasomal degradation of
a ubiquitin fusion degradation (UFD) substrate, a ubiquitin
ligase CRL2VHL substrate, and a ubiquitin-independent sub-
strate. Well characterized inhibitors that target different
aspects of the ubiquitin-proteasome system can be distin-
guished by their distinctive patterns of substrate stabilization,
enabling assignment of test compounds as inhibitors of the pro-
teasome, ubiquitin chain formation or perception, CRL activity,
or the UFD-p97 pathway.We confirmed that degradation of the
UFD but not the CRL2VHL or ubiquitin-independent substrates
depends on p97 activity. We optimized our suite of assays to
establish conditions suitable for high-throughput screening and
then validated their performance by screening against 160 cell-
permeable protein kinase inhibitors. This screen identified Syk
inhibitor III as an irreversible p97/vasolin containing protein
inhibitor (IC50  1.7 M) that acts through Cys-522 within the
D2 ATPase domain. Our work establishes a high-throughput
screening-compatible pipeline for identification and classifica-
tion of small molecules, cDNAs, or siRNAs that target compo-
nents of the ubiquitin-proteasome system.
The ubiquitin-proteasome system (UPS)3 comprises one of
the most important mechanisms for post-translational regula-
tion of protein function in eukaryotic cells. The UPS comprises
hundreds of enzymes that promote covalent attachment of
ubiquitin and UBL (ubiquitin-like) proteins to target proteins,
as well as enzymes that reverse the modification. Conjugation
of ubiquitin to target proteins is a multistep process (1–4).
First, ubiquitin is primed for transfer by the ubiquitin-activat-
ing enzyme (E1), to which it becomes attached via a thioester
bond between the C terminus of ubiquitin and the active site
cysteine of E1. Next, the activated ubiquitin is transferred from
E1 to the active site cysteine of a ubiquitin-conjugating enzyme
(E2). Finally, the E2ubiquitin thioester binds a ubiquitin ligase
(E3), and the ubiquitin is transferred to the side chain amino
group of a lysine residue on a substrate protein that is simulta-
neously bound to the same E3. Either this reaction can either
terminate, or additional ubiquitin transfers can occur to ubiq-
uitin itself, resulting in formation of a chain of ubiquitins
attached to the substrate. Attachment of ubiquitin or UBL pro-
teins to a target can yield diverse outcomes, including a change
in the activity, localization, binding partners, or stability of the
target. The most intensively studied consequence of ubiquiti-
nation is protein degradation. Polymerization of a chain linked
together via Lys-48 of ubiquitin typically results in rapid degra-
dation of the modified target by the 26 S proteasome. The pro-
teasome binds proteins bearing Lys-48-linked ubiquitin chains
and degrades themodified proteinwhile recycling the ubiquitin
for future use. The proteasome also degrades a handful of pro-
teins, including ornithine decarboxylase (ODC), in a ubiquitin-
independent manner (5). Given the importance of the UPS to
regulatory biology, there has been considerable interest in
developing small molecule inhibitors as potential therapies for
a range of human diseases. The UPS has been validated as an
important target in cancer by clinical use of the proteasome
inhibitor bortezomib (Velcade) for the treatment of multiple
myeloma andmantle cell lymphoma (6, 7). The success of bort-
ezomib has inspired interest in developing other UPS-directed
drugs (8) that have greater efficacy but fewer side effects.
The AAA (ATPase associated with diverse cellular activities)
ATPase p97 is conserved across all eukaryotes and is essential
for life in budding yeast (9) and mice (10). p97 is overexpressed
in several cancers, supporting the idea that it could be a target of
general importance in oncology (11, 12). Loss-of-function stud-
ies inmodel organisms indicate that p97 plays a critical role in a
broad array of cellular processes including Golgi membrane
reassembly (13), membrane transport (14, 15), degradation of
misfolded membrane and secretory proteins by the UPS (16,
17), regulation ofmyofibril assembly (18), cell division (19), and
formation of protein aggregates (20–22). This broad range of
functions is thought to derive from the ability of p97 to unfold
proteins or disassemble protein complexes. Several factors
make p97 an intriguing target for the development of drugs to
treat cancer. First, elevated expression levels of p97 have been
associatedwith poor prognosis of cancer (23, 24). Second, p97 is
an ATP hydrolase, and thus in theory, it should be druggable.
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Third, p97 is essential, and thus, p97 inhibitors should have
antiproliferative activity. In addition, p97 is essential for endo-
plasmic reticulum-associated degradation (ERAD) (15, 25, 26).
Blockade of ERAD is thought to be a keymechanismunderlying
the anticancer effects of bortezomib (27). Given that p97 is
implicated in ERAD but otherwise has a more restricted role in
theUPS comparedwith the proteasome, it is possible that drugs
that target p97might retain much of the efficacy of bortezomib
but with less toxicity.
EXPERIMENTAL PROCEDURES
Materials—The antibodies used in this study were anti-GFP
(BD Biosciences), anti-luciferase (Promega), and anti-p97
(ResearchDiagnostics).MG132was purchased fromBIOMOL.
Cycloheximide (CHX) and 3,4-methylenedioxy--nitrostyrene
(compound7) was purchased fromEMDBioscience. 3,4-Meth-
ylenedioxycinnamic acid (compound 18) was purchased from
Sigma. Thalidomide was purchased from AK Scientific. Cells
were grown on a 96-well CELLSTARblackClear bottomplate
(ISC Bioexpress) for live cell imaging on an ImageXpressMicro
automated microscope (Molecular Devices). Luciferase inten-
sity was determined on an Analyst AD plate reader (Molecular
Devices). The plasmids, primer sequences, cell lines, and siRNA
sequences used in this study are listed in supplemental Table 1.
RDB2004 was subjected to site-directed mutagenesis using
primers E305Q-F and E305Q-R to create QQ-p97 (RDB2405).
RDB2120 was subjected to site-directed mutagenesis using
primers C522A-F and C522A-R to create C522A-p97
(RDB2402).
Generation of Dual-reporter Stable Cell Lines—Lentiviruses
were packaged by cotransfection with helper plasmids in 293T
cells (DTC 20) (28) using FuGENE HD (Roche Applied Sci-
ence). UbG76V-GFP-expressing HeLa cells (DTC 9) were
infected with one of three lentiviruses expressing wild-type
luciferase (Luc; RDB2392), ODD-Luc (RDB2391), or Luc-ODC
(RDB2390) (29) andwere grown inDMEMcontaining puromy-
cin (2.5 g/ml) to establish stably transduced cell lines (DTC
23–25).
Reporter Accumulation Assay—Cells were seeded on 96-well
plates (5000 cells/well) and grown for 16 h. Cells were treated
with modified DMEM (without phenol red, folic acid, ribofla-
vin, and vitamin B12) containing dimethyl sulfoxide (DMSO),
MG132, or a test compound for 2–3 h. Two GFP images per
well with 100-ms exposure time were acquired by the auto-
mated microscope, and the average GFP intensity per area of
a cell was determined using the cell scoring function of
MetaXpress software. The mean GFP intensity of 500 cells
was calculated using Excel. Cells without theGFP reporterwere
used to do background correction. The effect of MG132 was
calculated by taking the normalized GFP intensity for cells
treated with MG132 and dividing by the same value obtained
fromDMSO-treated cells. Luciferase assays were carried out in
96-well white solid bottomplates. D-Luciferin (50l of 1mg/ml
in PBS) was added into each well containing 50 l of medium
and incubated at room temperaturewith shaking at 500 rpm for
5 min. Luminescence intensity was determined with 0.1-ms
integration time.
Reporter Degradation Assay—Cells were seeded on 96-well
plates (5000 cells/well) and grown for 16 h. Cells were treated
with modified DMEM (without phenol red, folic acid, ribofla-
vin, and vitamin B12) containing MG132 (4 M) for 1 h and
washed twice with prewarmed PBS (100 l). Modified DMEM
containing FBS (2.5%), CHX (30 g/ml), and DMSO or a test
compound (030 M) was added to each well. Plates were
imaged on the ImageXpressMicromicroscope at different time
points. For the ODD-Luc degradation assay, four identical
96-well white solid bottom plates were prepared. At each time
point, one plate was taken out of the incubator, and luciferase
activity was determined as described for the reporter accumu-
lation assay. Detailed methods for data analysis are described
under supplemental “Methods.”
Plasmid and siRNA Transfection—siRNA oligonucleotides
purchased fromThermoFisher Scientific orQiagenwere trans-
fected into cells using Lipofectamine RNAiMAX (Invitrogen),
and plasmids were transfected using FuGENEHD according to
the manufacturers’ protocols. Materials and additional meth-
ods are described under supplemental “Methods.”
RESULTS ANDDISCUSSION
Quantitative CHX Chase Assay in Live Cells to Monitor UPS
Function—Three dual-reporter stableHeLa cell lines were gen-
erated to monitor UPS function in mammalian cells. One
expressed the well characterized ubiquitin fusion degradation
(UFD) reporter UbG76V-GFP (30) and a recently described con-
struct that features the oxygen-dependent degradation domain
of HIF1 fused to luciferase (ODD-Luc) (29). The second
expressed UbG76V-GFP and luciferase fused to the ubiquitin-
independent degradation domain of ornithine decarboxylase
(Luc-ODC) (29). Schematic diagrams of these and other report-
ers used in this work are shown in supplemental Fig. 1. The
third line expressed UbG76V-GFP and unfused luciferase. As
expected based on prior work, the UbG76V-GFP and ODD-Luc
reporters accumulated by20-fold in cells treated with 7.5 M
MG132 for 2 h (Fig. 1A). However, the Luc-ODC reporter
exhibited only a modest 1.6-fold accumulation upon exposure
to 30 M MG132 for 2.5 h (Fig. 1B), which is consistent with
both the longer half-life of Luc-ODC (see below) and a previous
report (29). The unfused luciferase was used to weed out com-
pounds that affected luciferase activity.
Increases in the steady-state level of a protein depend on
rates of both protein synthesis and degradation. Therefore,
genetic manipulations or drugs that inhibit degradation might
give amisleading result if they also influence gene expression or
protein synthesis. For this reason, pulse-chase experiments are
widely acknowledged to be the gold standard for monitoring
protein degradation. However, published uses of the optically
active reporters described above have relied almost exclusively
on monitoring reporter accumulation as opposed to reporter
degradation (29–33). A potential problem with this approach
was noted by Alvarez-Castelao et al. (34), who demonstrated
that accumulation of three UPS reporters in response to pro-
teasome inhibitors is driven in large measure by up-regulation
of the constructs’ cytomegalovirus promoter. To diminish the
potential for “off-target” effects, we developed an assay to eval-
uate specifically the effect of genetic perturbations or drugs on
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protein degradation. A commonly used assay to monitor pro-
tein degradation in eukaryotic cells is the “cycloheximide
chase,” wherein CHX is added to cells, and the decay in the
steady-state level of a target protein is monitored by immuno-
blotting. Unfortunately, it was initially not possible to use this
simple approach to monitor UbG76V-GFP degradation due to
the nearly undetectable steady-state levels of this reporter in
unperturbed cells. Accordingly, we first increased the initial
level of UbG76V-GFP by reversibly inhibiting the proteasome
with MG132 (35). Because of the extremely rapid turnover of
UbG76V-GFP, even a very brief incubation (1–2 h) withMG132
was sufficient to yield a readily detectable signal. Importantly,
most established cell lines can withstand treatment with pro-
teasome inhibitors for many hours (36), and thus, a 1-h treat-
ment is anticipated to have aminimumeffect on physiology and
does not elicit detectable induction of the apoptotic pathway
(37). We then removed the MG132 and initiated a classical
CHX chase, which allowed us to monitor the half-life of
reporter degradation in the absence of confounding synthesis.
GFP intensity was monitored at the time of removal of MG132
(time 0 min) and every 20–25 min thereafter (Fig. 1C, closed
circles). The degradation rate constant (k) andhalf-life (0.693/k)
were obtained from the slope of plotting ln(normalized GFP
intensity) versus time (supplemental Fig. 2), starting 60 min
after initiation of the chase. ODD-Luc degradation assayed
under the same conditions yielded a similar curve (Fig. 1C, open
circles). Note that it was not necessary to pre-accumulateODD-
Luc or Luc-ODC with MG132 due to much more sensitive
detection of luciferase activity compared with fluorescence.
Thus, in subsequent experiments (Fig. 2, B–E), pre-accumula-
tion with MG132 was not employed. A representative example
of how we determined the half-maximal inhibitory concentra-
tion (IC50) of MG132 in the UbG76V-GFP degradation assay is
shown in supplemental Fig. 2.
Validation of Dual-reporter Cell Lines with Published Chem-
ical Inhibitors of the UPS—To benchmark our dual-reporter
HeLa cells, we evaluated their responses to known chemical
inhibitors of the UPS, including a reversible proteasome inhib-
itor (MG132 (35)), a covalent proteasome inhibitor (YU101)
(38), a covalent ubiquitin E1 inhibitor (PYR-41) (39), a
CRLCRBN ubiquitin ligase complex inhibitor (thalidomide) (40),
an SCFMet30 inhibitor (SMER3) (41), a p53-HDM2 inhibitor
(JNJ26854165) (42), and a Nedd8 E1 inhibitor (MLN4924) (43)
(Table 1). MG132 inhibited degradation of the UbG76V-GFP
and ODD-Luc reporters with similar IC50 values, whereas the
IC50 values obtained with the Luc-ODC reporter were3-fold
higher. YU101 behaved very similarly toMG132. PYR-41 inhib-
ited both UbG76V-GFP and ODD-Luc degradation but had no
effect on Luc-ODC degradation, which is consistent with ODC
being a ubiquitin-independent proteasome substrate (5).
Meanwhile,MLN4924 elicited strong stabilization ofODD-Luc
but had no effect on the other reporters (Table 1 and supple-
mental Fig. 3A). This result is consistent withODD-Luc being a
substrate for the ubiquitin ligaseCRL2VHL, the activity of which
is dependent on Nedd8 conjugation (44). The results with
MG132, PYR-41, and MLN4924 indicated that our reporters
behaved exactly as predicted. The different reporter assays
allowed us to generate a rubric that can be used to narrow the
field of targets for any chemical inhibitor of the UPS (Table 2).
Interestingly, our findings expand the range of biological
activity of SMER3 and JNJ26854165 beyond the targets that
were originally identified for these compounds. The ability
to define in greater depth the activity of these compounds
toward the UPS targets underscores the utility of our suite of
assays.
Using our rubric as a guide, we sought to evaluate a recently
described inhibitor of p97 complexes, Eeyarestatin I (EerI) (45).
EerI blocked degradation ofUbG76V-GFPwith an IC50 of 3.7M
(supplemental Fig. 4) (37), which is consistent with the pub-
lished report that this reporter accumulates in cells depleted of
p97 (31). Unfortunately, we could not assay EerI in high-
throughput format on the ODD and ODC reporters because it
FIGURE 1.Development of dual-reporter cell lines and a CHX chase assay
to monitor UPS function. A, HeLa cells stably expressing UbG76V-GFP and
ODD-Luc were treated with the indicated amounts of MG132 for 2 h. Signal
intensities for GFP and luciferase accumulation were normalized to values
obtained with DMSO-treated cells. B, same as A, except that cells expressing
UbG76V-GFP and Luc-ODC were used. C, the degradation rates of UbG76V-GFP
and ODD-Luc were determined by first accumulating the proteins in MG132
(4M for 1h) and thenwashingout thedrugandmonitoring the rate of signal
decay in a CHX chase.
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interfered with luciferase activity. Therefore, we assayed the
effect of EerI on ODD-Luc degradation by Western blotting
(supplemental Fig. 3B). EerI did not block ODD-Luc degra-
dation even when assayed at a concentration 5-fold higher
than its IC50 for inhibiting UbG76V-GFP degradation. These
data are consistent with EerI being a selective inhibitor of
p97 or its cofactors (see below for further justification of this
conclusion).
Dual-reporter Cell Lines Can Be Used to Distinguish p97-de-
pendent and p97-independent Degradation—Our observations
with EerI suggested that we could identifymolecules that selec-
tively block p97 activity but not other general components of
the UPS (e.g. proteasome and E1 enzyme) by seeking com-
pounds that stabilize UbG76V-GFP but not ODD-Luc. To vali-
date this hypothesis, we determined the degree to which the
reporters were stabilized by knocking down endogenous p97
with siRNA or overexpressing the ATPase-deficient mutant of
p97 (QQ-p97). Definitive confirmation of the p97 dependence
of UbG76V-GFP degradation was obtained from a CHX chase
experiment. Depleting p97 or expressing the QQ-p97 mutant
increased the half-life of UbG76V-GFP by 14–28-fold (Fig. 2A
and supplemental Table 2). By contrast, theODD-Luc and Luc-
ODC reporters behaved quite differently (Fig. 2, B–E). ODD-
Luc and Luc-ODC were not stabilized by either siRNA-
mediated depletion of p97 or expression of QQ-p97 (see
supplemental Table 1 for a summary of half-lives). The failure
of p97 siRNA to stabilize ODD-Luc was confirmed byWestern
blotting (supplemental Fig. 5, lanes 1–4). It is not presently
knownwhy someproteins (e.g.UbG76V-GFP) depend onp97 for
their degradation, whereas others (such asODD-Luc) do not. It
is thought that, for some substrates, p97 dependence may be
related to the exposure of unstructured regions (31). Regardless
of the underlying reason, UbG76V-GFP and ODD-Luc are con-
venient tools for monitoring p97-dependent and p97-inde-
pendent degradation within the UPS.
Screening of 160 Cell-permeable Protein Kinase Inhibitors
with Dual Reporters—To demonstrate the utility of our dual-
reporter cell lines for high-throughput screening (HTS) assay,
we first optimized multiwell plate-based assays to monitor
accumulation and degradation of both UbG76V-GFP andODD-
Luc. Three quality control parameters were calculated: (a) the
signal/base line ratio, (b) the coefficient of variation (S.D./
mean)  100), and (c) the Z-factor (1  ((3  (p  N))/
(P  N)), where  is the standard deviation and  is the
mean for positive (P) and negative (N) controls) (46).MG132 (2
M) was used as a positive control, and DMSO was used as a
negative control. In the 96-well plate format, all assays exhib-
ited a Z-factor0.5 (Table 3), which qualifies an assay forHTS
according to metrics established by the National Institutes of
Health for screens conducted within the Molecular Libraries
Probe Production Centers Network (grants.nih.gov/grants/
guide/pa-files/PAR-10–182.html#SectionI). The optimum
duration for both assays was 3 h after the addition of com-
pounds, and both assays allowed repetitive imaging of the same
plate at different time points to determine the kinetics of signal
change. A representative image from a 3-h UbG76V-GFP degra-
dation assay is shown in supplemental Fig. 6.
We next screened a collection of 160 cell-permeable protein
kinase inhibitors in 96-well plates using the degradation assay
(Fig. 3A and supplemental Table 3A). The rationale underlying
this screen is that protein kinase inhibitors typically target the
ATP-binding site, and we reasoned that some known kinase
inhibitors might cross-inhibit one of the ATPase active sites of
p97. We first evaluated the inhibitory effect of library com-
pounds on UbG76V-GFP degradation at 12 M. Thirty-four
compounds that exhibited 50% inhibition were subjected to
7-point titrations (4-fold serial dilutions starting at 30 M),
which yielded 29 compounds with IC50 values 20 M. These
compounds were further evaluated by Western blotting with
anti-GFP antibody to eliminate false positives due to com-
FIGURE 2. Degradation of luciferase reporters is independent of p97. To
evaluate the effect of p97 on three reporters, cells were transfectedwith con-
trol or p97 siRNA for 48 h. For overexpression of the ATPase-inactive mutant
of p97, cells were transiently transfected with QQ-p97 or WT p97 expression
plasmids and analyzed after 24 h. A, UbG76V-GFP degradation was measured
by CHX chase (see “Experimental Procedures”) in cells treated with siRNAs
directed against either luciferase (control) or p97. Successful depletion of p97
was confirmed by immunoblotting (see supplemental Fig. 4B). B–E, degrada-
tion of basal ODD-Luc (B and C) or Luc-ODC (D and E) was measured by CHX
chase assay (without preincubation in MG132) using dual-reporter cells that
were pretreated as follows. B and D, cells were transfected with siRNA
directed against p97 or non-silencing negative control. C and E, cells were
transfectedwithplasmids encodingeitherWTp97or dominant-negativep97
(QQ-p97).
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pound autofluorescence (14 compounds). The remaining 15
active compounds were assayed for their ability to inhibit deg-
radation of ODD-Luc and Luc-ODC, as well as their effects on
p97 ATPase and 26 S proteasome activities in vitro. The assay
results for these compounds plus two autofluorescent com-
pounds that blocked UbG76V-GFP degradation as determined
TABLE 1
Published chemical inhibitors of the UPS
*, Measurements were carried out in triplicate, and variance is expressed as the standard deviation. **, data were adapted from Ref. 37. Measurements were carried out in
triplicate, and variance is expressed as S.D. ***, NM, not measured due to interference with luciferase activity.
TABLE 2
Classification of potential targets for chemical inhibitors on the basis of their pattern of reporter stabilization
Reporter stabilizationa
Potential target Compound evaluatedbUbG76V-GFP ODD-Luc Luc-ODC
   Proteasome or other general UPS factor that is not ubiquitin-specific MG132, YU101, SMER3
   E1 enzyme or other Ub-specific factor PYR-41
   CUL2VHL or general cullin-RING ligase component MLN4924
   Not specified by these assays Thalidomide
   p97 or the UFD pathway EerIc
a , stabilization of the reporter;, little or no effect.
b EerI and JNJ26854165 were difficult to categorize using this suite of assays due to their interference with luciferase activity.
c Although EerI could not be evaluated using a luciferase readout, immunoblotting confirmed that it behaves as an inhibitor of the p97-UFD pathway (i.e. no accumulation or
stabilization of ODD-Luc and Luc-ODC reporters).
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by Western blotting are listed in Table 4 and supplemental
Table 3B. Several noteworthy findings emerged from this anal-
ysis. First, at least 8% (13/160) of the compounds in the com-
mercial library we screened inhibited degradation of at least
one of our reporters with an IC50 of10 M. By contrast to the
results obtained in the degradation assays, only one compound
TABLE 3
Summary of HTS quality control parameters for 96-well plates
Parameter
Accumulation Degradation
UbG76V-GFP reporter ODD-Luc reporter UbG76V-GFP reporter ODD-Luc reporter
S/Ba 3.4 11 2.6 5.8
CVb 3.3% (P), 1.9% (N) 7.3% (P), 4.5% (N) 7.4% (P), 7.3% (N) 8.2% (P), 7.6% (N)
Z-factorc 0.67 0.7 0.5 0.57
a S/B, signal/base line ratio.
b CV, coefficient of variation ((S.D./mean) 100).
c Z-factor 1 ((3 (p N))/(P N)), where  is S.D. and  is the mean for positive (P) and negative (N) controls. The positive control was MG132 (2 M), and
the negative control was DMSO (0.8%).
FIGURE 3. Identification of 3,4-methylenedioxy--nitrostyrene (compound 7) as an inhibitor of UbG76V-GFP and TCR-GFP degradation. A, summary
of the multistep screen of 160 protein kinase inhibitors. B, structure of compound 18. C, titration curves of MG132 and compounds 7 and 18 for inhibiting
UbG76V-GFPdegradation.D, the reversibility of compound inhibitionwasdeterminedby first accumulatingUbG76V-GFP in thepresenceofMG132 (4M for 1h),
washing out MG132, and exposing cells to CHX plus MG132 (10M) or compound 7 (15M) for 2 h and then washing out the test compound andmonitoring
decay of the GFP signal in CHX for 20 h. E, titration curves for inhibition of the in vitro ATPase activity of WT p97 (black curve) or C522A-p97 (gray curve) by
compound 7. F, HEK293 cells stably expressing the ERAD reporter TCR-GFP were used to determine the effect of compound 7 on the ERAD pathway. Cells
were treatedwithMG132, washed, and then incubated in the presence of CHXplus test compound for 2 h prior to harvest. Sampleswere immunoblottedwith
anti-GFP antibody to detect TCR-GFP. p97 served as a loading control.
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(7, Syk inhibitor III) inhibited p97 ATPase with an IC50 of10
M. Second, although most compounds exhibited similar IC50
values toward the three reporters, there were some interesting
differences. For example, herbimycin A (compound 6), Syk
inhibitor III (compound 7), and fascaplysin (compound 12)
exhibited very little activity in the Luc-ODC assay, implying
that they target some aspect of ubiquitin-dependent degrada-
tion. Meanwhile, two compounds (JNK inhibitor negative con-
trol (compound 14) and BAY 11-7082 (compound 9)) were
considerablymore potent in stabilizing the luciferase reporters,
implying that, in some unknown manner, they may stabilize
luciferase against proteasome-dependent turnover. Third,
compounds1–4, which targetAkt, stabilized all three reporters
but appeared to act by different mechanisms. Whereas com-
pounds 1 and 2 inhibited ATP-dependent 26 S proteasome
chymotrypsin-like activity with submicromolar IC50 values,
compounds 3 and 4 did not. This suggests the interesting pos-
sibility that compounds 1 and 2 may be inhibitors of one or
more of the six proteasomal ATPases. Taken together, our
observations on a small collection of kinase inhibitors highlight
the potential risk in interpreting results obtained with small
molecules before thoroughly evaluating their potential off-tar-
get effects.
Identification of an Irreversible p97 Inhibitor—Compound 7
(3,4-methylenedioxy--nitrostyrene) (47, 48) was repurchased
for amore detailed analysis due to its low IC50 values in both the
UbG76V-GFP degradation and in vitro ATPase assays and its
3.5-fold lower IC50 for p97-dependent versus p97-independent
reporters. Replacing the nitro group with a carboxylic acid
(compound 18) (Fig. 3B) greatly diminished activity (Fig. 3C),
suggesting that the nitro group was critical for the observed
inhibition. This implied that the primary mechanism of action
was covalent. Moreover, UbG76V-GFP was degraded in cells
treated with MG132 for 2 h and then transferred to fresh
medium containing CHX for 20 h but remained stable in cells
pretreated with compound 7 prior to CHX chase (Fig. 3D),
providing further support for the idea that the mechanism of
inhibition was irreversible. Electrophilic agents that react with
a nonessential cysteine (Cys-522) in the D2 domain active site
can irreversibly inhibit p97 (49). Therefore, we compared the
activity of compound 7 toward wild-type p97 and C522A-p97.
The poor activity of compound 7 toward the C522A mutant
suggested that electrophilic attack of Cys-522 is indeed critical
for the potency of compound 7 (Fig. 3E). p97 is perhaps best
known for its role in promoting ERAD (14). If compound 7
inhibits p97 in cells, it should block ERAD. To test this predic-
tion, we evaluated the impact of compound 7 on the ERAD
reporter TCR-GFP (-chain of the T-cell receptor fused to
GFP). TCR-GFP overexpressed in non-T-cells inserts into the
endoplasmic reticulum but behaves as an unfolded protein and
is degraded by the proteasome in a p97-dependent manner
(32). Consistent with its p97 inhibitory activity, compound 7
potently blocked degradation of TCR-GFP at 5 or 10 M
(Fig. 3F).
Compound 7 Exhibits Distinct Behavior in Degradation Ver-
sus Accumulation Assay—Our initial rationale for developing a
high-throughput degradation assay was to identify small mole-
cules or genetic constructs that block protein degradation inde-
pendent of any effects theymay have onmRNA transcription or
translation. To evaluate the potential for effects on reporter
accumulation to obscure effects on reporter degradation, we
rescreened the collection of 160 kinase inhibitors to identify
those compounds that promoted accumulation of UbG76V-
GFP. Interestingly, of those compounds shown in Table 4,
compounds 3, 7, and 10–12 did not score as positives in the
accumulation assay. To evaluate this discrepancy in more
depth, we measured the concentration-dependent accumu-
lation of UbG76V-GFP in response to compound 7 or its inac-
tive analog, compound 18 (Fig. 4A). When tested at 7.5 or 30
M, compound 7 elicited 2-fold accumulation of UbG76V-
GFP. By contrast, the same compound caused 2-fold stabili-
zation at 1.7 M and almost complete stabilization at 7.5 M
(Fig. 3C). Thus, the degradation assay was much more
responsive to compound 7, suggesting that this compound
may inhibit some step in expression of the UbG76V-GFP
reporter. To test this hypothesis, we assayed accumulation of
TABLE 4
Summary of 17 hits from the kinase inhibitor screen
Compound PubChem CID Description
IC50 (M)a
UbG76V-GFP ODD-Luc Luc-ODC p97 ATPaseb Proteasomec
1 5719375 Akt inhibitor IV 10	 2 5.0	 0.5 12	 5 12	 5 1.5	 0.3
2 10196499 Akt inhibitor VIII 3.7	 0.9 3.6	 0.5 2.9	 0.4 43	 4 3.7	 0.9
3 16760284 Akt inhibitor X 16	 9 14	 11 11	 5 50 40	 8
4 5113385 PDK1/Akt/Flt 0.52	 0.12 3.4	 0.9 3	 1 50 30
5 72311 Chelerythrine chloride 2.2	 1 3.4	 0.2 1.9	 0.7 24	 11 48	 8
6 16760502 Herbimycin A, Streptomyces sp. 2.8	 1.6 5	 2 30 50 30
7 672296 Syk inhibitor III 1.6	 0.4 5.9	 1.5 30 1.7	 0.5 162	 41
8 451705 Staurosporine, Streptomyces sp. 12	 2.0 19	 4 16	 4 50 8.0	 1.5
9 5353431 BAY 11-7082 3.0	 0.8 0.6	 0.08 0 .5	 0.1 12	 1 30
10 2794188 Cdk1 inhibitor 7.0	 1.0 15	 2 7.0	 2.0 17	 3 28	 5
11 481747 Cdk4 inhibitor III 2.8	 0.9 8.0	 2.0 7.2	 2.3 13	 0.5 30
12 73292 Fascaplysin 0.9	 0.1 6.9	 1.9 30 50 73	 14
13 5287844 GSK-3 inhibitor IX 12	 4 8.2	 2 1.0	 0.1 50 32	 8
14 11665831 JNK inhibitor, negative control 3.8	 0.8 0.15	 0.01 0.11	 0.01 50 30
15 490561 K-252a, Nocardiopsis sp. 10	 4 7.2	 1.4 2.5	 0.7 26	 2 9.2	 3.1
16 6711154 PKCbII/EGFRd inhibitor 10 10 NDd 50 30
17 9549300 Tpl2 kinase inhibitor 10 10 ND 50 30
aMeasurements were carried out in triplicate, and variance is expressed as S.D.
b The p97 ATPase assay is described under supplemental “Methods.”
c The human 26 S proteasome assay is described under supplemental “Methods.”
d EGFR, EGF receptor; ND, not determined.
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UbG76V-GFP in the presence of 4 M MG132 and compound
7 or 18 (Fig. 4B). Compound 7 inhibited MG132-induced
accumulation of the reporter with an IC50 of 2.1 	 0.5 M,
which explains why we observed only a small effect in the
accumulation assay (Fig. 4A).
In conclusion, we have described a set of dual-reporter cell
lines that stably express optically active proteins whose degra-
dations depend on different components of the UPS. Using
these cell lines, we have established live cell degradation assays
that employ the addition of MG132 to accumulate reporter,
followed by a shift to CHX to monitor the rate of decay of the
accumulated protein. Our approach can be broadly applied to
any unstable proteins whose steady-state levels are barely
detectable. Adapting our assays to an automated microscope
platform enabled time-lapse analysis of the same plate and high
speed data acquisition with high statistical reliability (Z-factor
0.5 for all assays). At maximum throughput, the degrada-
tion assays as configured here can be used to screen 12,000
wells per day. Thus, even though monitoring reporter deg-
radation involves more manipulation than monitoring accu-
mulation, it is nevertheless suitable for HTS of sizable librar-
ies. The dual-reporter cell lines and assay methods reported
here can be used to rapidly categorize small molecule inhib-
itors and should be equally applicable to screen for and clas-
sify siRNAs, cDNAs, and peptides that have an impact on
UPS function.
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